Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Swedish Orphan Biovitrum    SOBI   SE0000872095

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Stockholm
11/13/2017 11/14/2017 11/15/2017 11/16/2017 11/17/2017 Date
116.9(c) 116.9(c) 116.9(c) 121(c) 120.1(c) Last
347 499 342 911 415 453 493 306 549 354 Volume
-0.68% 0.00% 0.00% +3.51% -0.74% Change
More quotes
Financials ( SEK)
Sales 2017 6 385 M
EBIT 2017 1 514 M
Net income 2017 1 056 M
Finance 2017 1 028 M
Yield 2017 0,15%
Sales 2018 7 902 M
EBIT 2018 2 264 M
Net income 2018 1 692 M
Finance 2018 2 253 M
Yield 2018 0,42%
P/E ratio 2017 29,89
P/E ratio 2018 18,86
EV / Sales2017 4,96x
EV / Sales2018 3,86x
Capitalization 32 728 M
More Financials
Company
Swedish Orphan Biovitrum AB engages as a biopharmaceutical company.It provides therapies and services for patients with rare diseases.The firm's core products include Kineret within the inflammation therapeutic area; and Orfadin, Ammonaps, and Ammonul within the genetics and metabolic therapeutic... 
Sector
Pharmaceuticals
Calendar
02/22Earnings Release
More about the company
Surperformance© ratings of Swedish Orphan Biovitrum
Trading Rating : Investor Rating :
More Ratings
Latest news on SWEDISH ORPHAN BIOVITRUM
11/17 SWEDISH ORPHAN BIOVITRUM : First patient randomised in study evaluating safety a..
11/16 SWEDISH ORPHAN BIOVITRUM : First patient randomised in a phase 3 study evaluatin..
11/02 SOBI : Alprolix® Approved in the Kingdom of Saudi Arabia for the Treatment of Ha..
11/02 SWEDISH ORPHAN BIOVITRUM : The First Patient Enrolled in the ReITIrate Study Eva..
11/02 SWEDISH ORPHAN BIOVITRUM : Interim data published in Haemophilia show improvemen..
10/31 SWEDISH ORPHAN BIOVITRUM : Interim data published in Haemophilia show improvemen..
10/27 SWEDISH ORPHAN BIOVITRUM : Sobi publishes its report for the third quarter 2017
10/25 SWEDISH ORPHAN BIOVITRUM : The first patient enrolled in the ReITIrate study eva..
10/25 SWEDISH ORPHAN BIOVITRUM : Alprolix® approved in the Kingdom of Saudi Arabia for..
10/25 SWEDISH ORPHAN BIOVITRUM : Sobi™ publishes its report for the third quarte..
More news
Sector news : Pharmaceuticals - NEC
12:17aDJADRs End Higher; JA Solar, NetEase Trade Actively
11/17 British stocks fall back as Carillion crashes, Sky soars
11/17DJROCHE : U.S. FDA Approves Roche's Gazyva for Untreated Follicular Lymphoma
11/17DJROCHE : to Acquire U.S. Software Company Viewics
11/16 Europe approves GlaxoSmithKline's new triple lung drug
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
10/31 Bioverativ's Eloctate demonstrates positive effect on joints in hemophilia A ..
10/25 Swedish Orphan Biovitrum AB ADR 2017 Q3 - Results - Earnings Call Slides
04/13 BIOVERATIV : Just Stop The Bleeding
02/21 Sobi inks Ammonul distribution deal with Valeant
2016 Reassessing Biogen
Chart SWEDISH ORPHAN BIOVITRUM
Duration : Period :
Swedish Orphan Biovitrum Technical Analysis Chart | SOBI | SE0000872095 | 4-Traders
Technical analysis trends SWEDISH ORPHAN BIOVITRUM
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 125  SEK
Spread / Average Target 4,1%
EPS Revisions
Managers
NameTitle
Guido Oelkers President & Chief Executive Officer
Sven Håkan Björklund Chairman
Mats-Olof Wallin Chief Financial Officer & Senior Vice President
Marianne Keisu Chief Medical Officer & Vice President
Milan Zdravkovic Senior Vice President, Head-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SWEDISH ORPHAN BIOVITRUM9.56%3 878
JOHNSON & JOHNSON20.74%373 077
NOVARTIS10.73%218 225
PFIZER8.87%211 963
ROCHE HOLDING LTD.-2.06%200 423
MERCK AND COMPANY-6.91%150 468